- Home
- MODD vs RPTX Comparison
MODD vs RPTX Comparison
Compare MODD & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- RPTX
- Stock Information
- Founded
- MODD 1998
- RPTX 2016
- Country
- MODD United States
- RPTX Canada
- Employees
- MODD N/A
- RPTX N/A
- Industry
- MODD Industrial Specialties
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- RPTX Health Care
- Exchange
- MODD Nasdaq
- RPTX Nasdaq
- Market Cap
- MODD 46.8M
- RPTX 54.0M
- IPO Year
- MODD N/A
- RPTX 2020
- Fundamental
- Price
- MODD $1.08
- RPTX $1.29
- Analyst Decision
- MODD Buy
- RPTX Strong Buy
- Analyst Count
- MODD 1
- RPTX 3
- Target Price
- MODD $5.00
- RPTX $7.00
- AVG Volume (30 Days)
- MODD 69.5K
- RPTX 232.9K
- Earning Date
- MODD 02-13-2025
- RPTX 03-03-2025
- Dividend Yield
- MODD N/A
- RPTX N/A
- EPS Growth
- MODD N/A
- RPTX N/A
- EPS
- MODD N/A
- RPTX N/A
- Revenue
- MODD N/A
- RPTX $66,524,000.00
- Revenue This Year
- MODD N/A
- RPTX $12.15
- Revenue Next Year
- MODD N/A
- RPTX N/A
- P/E Ratio
- MODD N/A
- RPTX N/A
- Revenue Growth
- MODD N/A
- RPTX 18.19
- 52 Week Low
- MODD $1.07
- RPTX $1.10
- 52 Week High
- MODD $2.65
- RPTX $7.45
- Technical
- Relative Strength Index (RSI)
- MODD 27.02
- RPTX 47.52
- Support Level
- MODD $1.08
- RPTX $1.13
- Resistance Level
- MODD $1.28
- RPTX $1.37
- Average True Range (ATR)
- MODD 0.07
- RPTX 0.09
- MACD
- MODD -0.00
- RPTX 0.04
- Stochastic Oscillator
- MODD 4.46
- RPTX 57.14
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.